Our Neuroscience Leadership Team
BILL MARTIN, PH.D.
GLOBAL THERAPEUTIC HEAD
Bill Martin, Ph.D., is Global Therapeutic Head for Neuroscience at Janssen Research & Development, LLC, one of the Johnson & Johnson pharmaceutical companies. Prior to joining Janssen R&D, Bill was President and Chief Executive Officer of Blackthorn Therapeutics, and previously served as the company’s Chief Scientific Officer and Head of R&D. He co-founded Blackthorn, which integrates computational and clinical neuroscience and applies a precision medicine approach to creating novel therapeutics for central nervous system (CNS) disorders.
Before Blackthorn, Bill held multiple leadership positions at Theravance Biopharma, including leading the company’s research portfolio planning initiative and serving as a member of the strategic partnership team and project team leader for an advanced clinical stage CNS program. He began his career at Merck, where he contributed to the strategic direction of the company’s Neuroscience franchise.
Bill is a member of the Board of Directors for Brown University’s Carney Institute for Brain Science and has held leadership positions in the Society for Neuroscience, the American Physiology Society and the International Brain Research Organization. He has published extensively on neuroscience and brain disorders, with more than 75 publications in scientific journals.
Bill received a bachelor’s in Psychology from Swarthmore College and a doctorate in Experimental Psychology from Brown University. He conducted postdoctoral research at the Keck Center for Integrative Neuroscience at the University of California, San Francisco.
Bill Martin, Ph.D.
Global Therapeutic Head
ERIC SCHAEFFER, PH.D.
BOSTON INNOVATION CENTER
Eric Schaeffer, Ph.D. received his degree from the Albert Einstein College of Medicine in New York City, and went on to do post-doctoral fellowships at the Massachusetts Institute of Technology (MIT) and Rockefeller University in New York. In 1994, Eric joined the Molecular Sciences department at Pfizer in Groton, Connecticut, where he held several positions within the Molecular Sciences and Neuroscience Discovery departments, ultimately as a Senior Director of Neuroscience Research, leading in vitro and in vivo pharmacology groups. While at Pfizer, Eric was involved in advancing several compounds into early development for the treatment of depression, anxiety and bipolar disorder, and played a key role on the team that discovered the first FDA-approved non-nicotine replacement therapy for smoking cessation.
In 2009, Eric joined the Cure Huntington's Disease Initiative (CHDI) Foundation as Director of Neuropharmacology, where he led drug discovery teams in the identification of novel treatments for Huntington’s disease. In 2010, Eric accepted a position at Bristol Meyers Squibb as Director of Neuroscience Clinical Biomarkers, where he was responsible for the translational medicine strategy and tactics for the psychiatry portfolio. In 2014, Eric joined Janssen R&D as Senior Director in the Neuroscience External Innovations group. In his current role, Eric is responsible for managing a range of biotech and academic alliances focused on delivering novel therapies for the treatment of severe mood disorders and Alzheimer’s disease.
Eric Schaeffer, Ph.D.
Boston Innovation Center
GUY R. SEABROOK, PH.D.
VICE PRESIDENT & GLOBAL LEAD
NEUROSCIENCE EXTERNAL INNOVATION
JOHNSON & JOHNSON INNOVATION CALIFORNIA
Guy R. Seabrook, Ph.D. joined Janssen in 2012. His role as the Neuroscience Lead for the newly formed Johnson & Johnson Innovation, California is to help co-create and implement the external innovation plan to deliver the Neuroscience Therapeutic Area R&D Strategy. This includes solidifying Janssen’s place as an ideal partner in a highly competitive landscape of external collaborations. Our goals are to identify the best opportunities for value-generating collaborations and develop an industry-leading portfolio of investment opportunities. This involves the cultivation of a strong scientific network of experts in the global innovation community. He has more than 23 years of experience in drug discovery research, which includes preclinical research on marketed products and candidates in clinical development. Formerly, Guy was part of Eli Lilly’s Global External Research & Development (GER&D) organization where he led the GER&D team for the Lilly Bio-Medicines Business Unit, and also at Merck & Co, Inc., where he was the Head of the West Point Department of Alzheimer's Disease Research. He graduated with a Ph.D. in Zoology from the University of Nottingham, United Kingdom in 1987, and completed his postdoctoral research at the University of Miami School of Medicine, in Miami, Florida.
Guy R. Seabrook, Ph.D.
Vice President & Global Lead
Neuroscience External Innovation
Johnson & Johnson Innovation California
JOHAN L. J. VERBEECK, D.V.M., MS.c
VICE PRESIDENT EXPERIMENTAL MEDICINE
JANSSEN RESEARCH & DEVELOPMENT, LLC
Luc is a highly regarded expert in early clinical and non-clinical development with a strong track record in developing and applying translational experimental medicine models and biomarkers. He is a strong leader of people and teams, and has held management roles in clinical medicine and in global public health.
As leader of the Experimental Medicine group, Luc oversees design of clinical strategies and execution of clinical trials through Proof of Concept for all new molecular entities generated in the Janssen Neuroscience Therapeutic Area (TA). He has successfully integrated medical expertise into the drug discovery and early development process. Luc also serves as a member of the Janssen R&D Neuroscience Senior Leadership team.
He deployed the fast and lean process of clinical plan development, protocol development and trial execution, including lean trial visualization, and initiated several early development process improvement activities within and outside the Experimental Medicine group and across the five therapeutic areas. He served as Compound Development Team leader for several projects in early and late development. Luc maintains close and fruitful collaboration with external partners, the Johnson & Johnson Innovation Centers, and academic institutions.
Luc is chairman of the Neuroscience TA Discovery/Development Review Committee (DDRC) for Early Development. He also chairs the cross-TA Early Development Head Meeting, the Neuroscience Network Meeting in Beerse, and he is a member of the Johnson & Johnson First-In-Human Committee and the Janssen Campus R&D Senior Leadership Team in Beerse, Belgium.
Luc joined Janssen Research Foundation in Beerse in 1989 and advanced through a variety of management positions, including Clinical Research Manager and Senior Clinical Research Manager, Cardiovascular Medicine; Associate Director, Internal Medicine; Director, Global Gastroenterology; Senior Director, Global Experimental Therapeutics and Human Pharmacokinetics; Executive Director-Project Champion, Drug Evaluation; and Vice President, Experimental Medicine, Europe. He was named to his current role in 2009.
Before Luc joined Janssen, he practiced medicine and held management positions in clinical medicine and public health at St. Erasmus Hospital in Antwerp, Belgium, and The Ministry of Health, Zimbabwe, Africa.
Luc earned a medical degree from Catholic University, Louvain, Belgium, and completed postgraduate training in Tropical Medicine at Prince Leopold Institute, Antwerp. He also studied at the Vlerick School for Management, Leuven, Belgium. He is the author or coauthor of more than 75 publications and abstracts.
Luc Van Nueten
JANSSEN RESEARCH & DEVELOPMENT
Lucinda (Cindy) Warren is Vice President, Business Development, Neuroscience, which includes scientific finding, licensing transactions, mergers, acquisition, out licensing and alliance management.
With more than 23 years of broad industry experience, Lucinda began her pharmaceutical career in Canada. In 1999, she joined the Johnson & Johnson Family of Companies and has held various United States and Global roles of increasing responsibilities, including Sales, Marketing, New Product Development, Alliance Management, and Business Development Leadership. Lucinda has been responsible for the leadership and oversight of some of Janssen’s longest and largest global commercial alliances.
Prior to joining the Janssen Development Leadership Team, Lucinda led the Immunology Business Unit in Australia, returning to the U.S. in 2014 as Vice President, Alliance Management, responsible for leading the Pharmaceutical portfolio of collaborations.
Lucinda earned her Bachelor of Science from the University of Alberta, Canada.